FoRx Therapeutics AG (FoRx) is developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways. The company’s scientific foundations are built on the pioneering work of Professor Thanos Halazonetis, from the University of Geneva. Professor Halazonetis discovered novel DNA repair pathways, such as Break Induced Replication (BIR), that enable cancer cells to overcome DNA Replication Stress, a prevalent feature in human cancers but absent in normal, healthy cells. These repair pathways constitute a vulnerability that can be exploited for targeted intervention using synthetic lethality. The company’s investors include M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, and LSP (Life Sciences Partners). The company is based in Basel, Switzerland.